Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN versus LINCOMYCIN HYDROCHLORIDE.
Clindamycin vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
150-450 mg orally every 6 hours; 600 mg to 1.2 g intravenously every 6-8 hours; maximum 4.8 g/day IV.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
2.4 hours (range 1.5-5.1 hours) in adults with normal renal function; prolonged in severe hepatic impairment.
Clinical Note
moderateClindamycin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Clotrimazole
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10% of active drug and 90% as inactive metabolites via renal (feces 3.6% as active, bile significant for enterohepatic circulation).
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Clindamycin."